The Eli Lilly & Co. Logo at the company’s digital health innovation hub facility in Singapore, on Chiursday, Nov. 14, 2024.
Ore Huiying | Bloomberg | Getty Images
Eli lilly on thursday said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide Later this year, a few months earlier than anticipated.
The company expects to provide results from a 68-wheelk study in people with obesity and osteoarthritis of the knee in 2025, according to fourth -Quarter Earnings slides on its website. Eli Lilly Previously said that phase three study was expected to Finish in February 2026.
It is amon at least nine closely watched clinical trials on retrutide, which works differently from the obesity and diabetes treats on the market and appars to beed more Effects.
“We believe this potential new medicine can deliver even Aid during an earnings call on Thursday.
Retatrutide is a key part of eli lilly’s drug pipeline that could help the company maintenance its dominance in the blockbuster weight loss and diabetes treatment space and Diabetes Treatment Space and Come Novo Nordisk,
Dubbed the “triple g” drug, retatrutide works by Mimicking Three Hunger-Regulating Hormones: GLP-1, GIP and Glucagon. That appears to have more potent effects on a person’s appetest and satisfaction with food than other treatment.
Tirzepatide, the active ingredient in Eli Lilly’s Weight Loss Shot Zepbound and Diabetes Drug Mounjaro, MIMICS Two of the Hormones, GLP-1 and GIP. Novo Nordisk’s Weight Loss Drug Wegovy Mimics Only GLP-1.
Retatrutide appears to cause even weight loss than tirzepatide, which has skyrocked in demand in the US
Retatrutide helped patients lose 24.2% of their body weight, or 58 pounds, on average after 48 weeks in a midstage trial on adults who were obese or overweight. Thos who took the placebo loss 2.1% of their body weight after that same time period.
Higher doses of tirzepatide helped patients with obesity lose up to 22.5% of their body weight on average in late-stage studies.
– CNBC’s Angelica peebles contributed to this report.
(tagstotranslate) novo nordisk a/s
